Aeterna completes late-stage study of Zoptrex in endometrial cancer, top-line data expected in April, shares ahead 23%

• Thinly traded nano cap Aeterna Zentaris (NASDAQ:AEZS +23.1%) reaches the clinical endpoint in its Phase 3 study, ZoptEC, assessing Zoptrex (zoptarelin doxorubicin) in women with treatment-resistant advanced endometrial cancer. Data lock and the release of top-line results should happen in April. Enrollment was completed in June 2015 and the final dosing was completed in January 2016.
• The primary endpoint is overall survival compared to doxorubicin alone.
• Zoptrex combines a synthetic peptide carrier with the chemo agent doxorubicin. The carrier, a modified natural hormone with a strong affinity for the LHRH (luteinizing hormone-releasing hormone) receptor, enables the selective delivery of the chemo agent to LHRH receptor-positive tumors.